Relative Effectiveness of Adjuvant Chemotherapy for Invasive Lobular Compared With Invasive Ductal Carcinoma of the Breast
Relative Effectiveness of Adjuvant Chemotherapy for Invasive Lobular Compared With Invasive Ductal Carcinoma of the Breast
复制标题
DOI：
10.1002/cncr.30699
复制
发表时间：
2017-08-15
期刊：
影响因子：
6.2
通讯作者：
Tuttle, Todd M.
中科院分区：
文献类型：
--
作者：
Marmor, Schelomo;Hui, Jane Yuet Ching;Tuttle, Todd M.
背景：浸润性导管癌（IDC）和浸润性小叶癌（ILC）具有不同的临床、病理和基因组特征。本研究的目的是比较辅助化疗对ILC和IDC患者生存的相对影响。方法：从2000年至2014年加州癌症登记处确定接受内分泌治疗的雌激素受体（ER）阳性，人表皮生长因子受体1 （HER2）阴性，I/II期IDC和ILC的女性。收集患者、肿瘤和治疗特征。使用Kaplan-Meier方法和Cox比例风险模型估计10年总生存期（OS）。结果：总共有32997名女性患有IDC， 4638名女性患有ILC。在研究期间，两种亚型的化疗接受量均显著减少。对于IDC患者，单独接受内分泌治疗的10年OS率为95%，而接受内分泌治疗的10年OS率为93% (P
BACKGROUND: Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) have distinct clinical, pathologic, and genomic characteristics. The objective of the current study was to compare the relative impact of adjuvant chemotherapy on the survival of patients with ILC versus those with IDC. METHODS: Women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 1 (HER2) -negative, stage I/II IDC and ILC who received endocrine therapy were identified from the 2000 to 2014 California Cancer Registry. Patient, tumor, and treatment characteristics were collected. Ten-year overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional-hazards modeling. RESULTS: In total, 32,997 women with IDC and 4638 with ILC were identified. The receipt of chemotherapy significantly decreased during the study for both subtypes. For patients with IDC, the 10-year OS rate was 95% among those who received endocrine therapy alone versus 93% (P